Bridge Biotherapeutics reinforces its strategic focus on disease areas with significant unmet medical needs and lacks novel approved therapies, including cancers and various fibrotic diseases. Relating to idiopathic pulmonary fibrosis, the company has been accelerating the development of B BT-877 (an autotaxin inhibitor), B BT-301 (an ion channel modulator), and B BT-209 (a GPCR19 agonist).